Promising preclinical activity of NVL-655 presented by ⁦Nuvalent⁩ as a rationale for the ongoing ALKOVE1 trial opening at 3 sites in Europe right now ⁦⁦⁦Benjamin Besse⁩ ⁦Sanjay Popat⁩ ⁦Enriqueta Felip⁩

NVL-520. Next generation ROS1 TKI. Fresh out of press at ENA202 meeting. Alexander Drilon MD #ena2022

Resistance to specific RET inhibitors is quite heterogeneous, with only 14% on-target resistance mechanisms. Large study in 100+ patients on primary and secondary resistance. It will not ease the development of 2nd gen inhibitors! #ENA2022 Mihaela Aldea Arianna Marinello

Important to retain CNS efficacy and NVL-520 showing intracranial activity in refractory settings. Very promising #ROS1 inhibitor going forward. Congratulations to authors. Excited to now have this trial open at Georgetown University Georgetown Lombardi #LCSM #ENA2022

NVL-520 efficacy impressive already. RR 48%, but need to look at specific populations. With #ROS1 G2032R, RR 78% (7/9)! In pts with prior lorlatinib or repotrectinib, RR 50% (9/18). Still in escalation and 76% of pts still on therapy. Median time to response: 3.6 weeks. #ENA2022

Indeed, the safety profile of NVL-520 looks very promising. No DLTs, no treatment-related SAEs, no AEs leading to dose reduction or discontinuation. No dizziness (due to lack of NTRK inhibition). Early days (n=35) but very encouraging. #ENA2022

Early results from phase I ARROS-1 trial: NVL-520 in #ROS1 by Dr. Alexander Drilon MD at #ENA2022 . This novel ROS1 inhibitor is designed to avoid #NTRK (and TRK-related toxicities, which often limit dose intensity). Studied in a heavily pretreated population (71% with ≥2 TKIs and chemo)

A new 2nd gen ROS1 inhibitor is born!
In 21 évaluable pts w ROS1+ NSCLC, 10 (48%) had a partial response with NVL-520, although dose escalation is still ongoing. NVL-520 spares TRK2 (so no dizziness), good safety profile in 35 pts, all doses. #ENA2022 The ROS1ders, Inc. Alexander Drilon MD

UNICORN: An international real-world study of #osimertinib for uncommon #EGFR mutations as a first line setting further clarifies the drug's impact in patients with uncommon EGFR mutations. bit.ly/3StwroQ #LCSM Jair Bar Martin Reck Hochmair Maximilian Sandip Patel MD Shiruyeh Schokrpur, MD, PhD

Wishing everyone a very happy and joyous Divali

Excellence in Oncology Care - EIOC Kaltar Das Diaeddine Trad Vanita Noronha, MBBS MD DM Sanjay Popat Shaheenah Dawood Nice cases; genotyping in early stage disease…..pitfalls of interpretation. Increasingly a distinct skill that every thoracic oncologist needs

Interesting topic presented by Sanjay Popat on How to read and interpret a Molecular Profiling Report: What a Community Oncologist needs to know

#eioc #eioc 2022 #APMEA #MTB

Sanjay Popat walks us through how to interpret molecular profiling reports at the #EIOC2022

Happening now in 3rd Athenian Oncology Congress #3rdAOC : Professor Sanjay Popat from The Royal Marsden NHS Foundation Trust on an elegant presentation on indications for adjuvant Immunotherapy in resected #NSCLC
OncoAlert #some #LCSM

Your OncoAlert network is proud to be Live Covering the 3rd Athenian Oncology Congress happening October 21-22, 2022 in Athens Greece🇬🇷

An Amazing line up Petros Grivas Giannis Mountzios Jarushka Naidoo Vivek Subbiah, MD Maria Vakalopoulou Sanjay Popat Paolo Tarantino Stephen V Liu, MD & many more!

🔥🆕 in Lung Cancer Journal 🫁
Management of cutaneous tox under #amivantamab in pts with metastatic NSCLC harboring #EGFR Exon20ins: towards a proactive, multidisciplinary approach #LCSM

Find it here: lungcancerjournal.info/article/S0169-…

🆕✨ in Lung Cancer Journal , a very hot topic for patients, clinicians & researchers

#Leptomeningeal metastases in NSCLC: Diagnosis and treatment* #LCSM #cancer #oncology

🔗 Read it here: lungcancerjournal.info/article/S0169-…

Another impressive achievement from one of The Royal Marsden NHS Foundation Trust NIHR BRC at The Royal Marsden and the ICR Early Detection centre's rising stars! Well done Sumeet Hindocha! #earlydiagnosis (of recurrence)